IPO Databook: Encore Medical (EMI US) - Sep 2026

155 Views17 Jul 2026 10:02

SUMMARY

Encore Medical is a structural heart device company dedicated to transcatheter closure of certain cardiac defects, with devices offering multi-element frame construction and anatomical adaptability.
The company has over 35,000 successful global implants, with a potential U.S. market for PFO products exceeding $1.5 billion.
Encore Medical reported 2025 revenue of $2,585,858 and net losses, with auditors raising substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream